Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03666273
Title A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bayer
Indications

Advanced Solid Tumor

cervical cancer

gastric adenocarcinoma

transitional cell carcinoma

gastroesophageal junction adenocarcinoma

head and neck squamous cell carcinoma

Therapies

BAY1905254

BAY1905254 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.